Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-patient trial of JNJ-40411813 in schizophrenia
2010-023369-23Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of adx-71149 in schizophrenia (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Safety and tolerability of JNJ-40411813 and Exploratory therapeutic efficacy of JNJ-40411813. Started Dec 2010; status: terminated.
02
Drugs
adx-71149
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2010-023369-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023369-23.